Participants
| Role | Name | HCID | Charge |
|---|
| Reactant | Piperidine | HCID 8082 | — |
| Reactant | Diisopropylethylamine | HCID 81531 | — |
| Reactant | Methanaminium, N-((dimethylamino)(3H-1,2,3-triazolo(4,5-b)pyridin-3-yloxy)methylene)-N-methyl-, hexafluorophosphate(1-) (1:1) | HCID 9886157 | — |
| Reactant | HCID 131730749 | HCID 131730749 | — |
| Solvent | Dimethylformamide | HCID 6228 | — |
| Solvent | N-methyl-2-pyrrolidone | HCID 13387 | — |
| Product | L-Glutamic Acid | HCID 33032 | — |
Reaction Steps
Approximately 10 mg of Fmoc-Glu-Fib-Trityl-chloride resin was treated with 20% (v/v) piperidine in DMF (2 mL×1 min, filtered, then 2 mL×5 min), filtered and washed (NMP). 4-(Fmoc-aminomethyl)benzoic acid (P/N: Fluka, 04062; 10 eqv to Glu-Fib amount on the resin) was individually activated with HATU (P/N: Applied Biosystems 4317033, 9.5 eqv) and N,N-Diisopropylethylamine (30 eqv) in NMP (˜1 mL), added to the resin and mixed for 30 min. Resin was then filtered, washed with NMP, and the Fmoc group was cleaved. Piperazine acetic acid-TFA salt (10 eqv) was then activated using HATU (9.5 eqv) and N,N-Diisopropylethylamine (60 eqv) in NMP (˜1.5 mL) and added to the resin. After 30 min resin was washed with NMP followed by CH3CN. Conjugated peptide was cleaved (and deprotected) from resin using 95:5 TFA-water (200 μL, 2 h) and precipitated using Et2O. Analysis of compound (39) (see FIG. 30) was performed using ES-MS (direct infusion in water, Calculated [M+H]+=1829.8, Observed [M+H]+=1829.9)
Provenance & Evidence
| DOI | 10.6084/m9.figshare.5104873.v1 |
|---|
| Patent number | US08501498B2 |
|---|
| Source dataset | uspto-grants-2013_08 |
|---|
| ORD ID | ord-03c2542a2b594dc8b8ddfe82637ff096 |
|---|
| Source note | uspto-grants-2013_08 |
|---|